Evom­mune rais­es $50M to fund clin­i­cal tri­als in skin dis­eases

Evom­mune has raised a $50 mil­lion fund­ing round that it plans to use to bankroll a se­ries of clin­i­cal tri­als over the next two years for skin dis­eases, a bet that the ex­ec­u­tive team can repli­cate the suc­cess they had at their past com­pa­nies that were sold to Big Phar­ma buy­ers.

The com­pa­ny has a Phase IIa tri­al of its ex­per­i­men­tal drug EVO101, which tar­gets IRAK4, in atopic der­mati­tis. The drug was li­censed from Eli Lil­ly af­ter the drug­mak­er made a deal for Der­mi­ra in 2020. The near­ly 120-pa­tient tri­al of the drug is slat­ed to read out this sum­mer, CEO and co-founder Luis Peña told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER